Psychostimulants in the treatment of children diagnosed with ADHD: Risks and mechanism of action

Article type: Research Article

Authors: Breggin, Peter R.^;

Affiliations: Director, International Center for the Study of Psychiatry and Psychology (ICSPP)

Note: [] Correspondence: P.R. Breggin, MD, 4628 Chestnut Street, Bethesda, MD 20814, USA.

Abstract: Millions of children in North America are diagnosed with attention deficit/hyperactivity disorder and treated with psychostimulants such as methylphenidate, dextroamphetamine, and methamphetamine. These drugs produce a continuum of central nervous system toxicity that begins with increased energy, hyperalertness, and overfocusing on rote activities. It progresses toward obsessive/compulsive or perseverative activities, insomnia, agitation, hypomania, mania, and sometimes seizures. They also commonly result in apathy, social withdrawal, emotional depression, and docility. Psychostimulants also cause physical withdrawal, including rebound and dependence. They inhibit growth, and produce various cerebral dysfunctions, some of which can become irreversible. The “therapeutic” effects of stimulants are a direct expression of their toxicity. Animal and human research indicates that these drugs often suppress spontaneous and social behaviors while promoting obsessive/compulsive behaviors. These adverse drug effects make the psychostimulants seemingly useful for controlling the behavior of children, especially in highly structured environments that do not attend to their genuine needs.

Journal: International Journal of Risk and Safety in Medicine, vol. 12, no. 1, pp. 3-35, 1999